Eighty-five percent of medical research applications submitted to governments globally go unfunded. Many innovations die due to lack of capital. They may have saved many lives.
The global biotechnology market is expected to reach USD 727.1 billion by 2025.
The first new digital token launch through a tradable Structured Product security (AVEX.AI) on the Six (Swiss Stock Exchange).
The BIOSPHERES platform will launch with over USD 1 billion worth of medical solutions offerings that address major diseases like Alzheimer’s and ALS.
THE NEW PATH TO PATIENT-DRIVEN TREATMENTS AND CURES
Aevolve is a protocol that supports medical innovations from R&D stages to full-scale commercialization, by connecting patients, investors, and scientific innovators.
INVESTOR ACCESS TO A BILLION-DOLLAR ECOSYSTEM
This new asset class provides exposure to opportunities in blockchain, free of the risks associated with previous token offerings. Coming soon to the the SIX Swiss Stock Exchange.
FOR PATIENTS AND INNOVATORS
This innovation marketplace connects patients and the global community directly with scientific innovators and experts from all over the world to address various stages of the innovation life cycle.
AVEX Token & The Aevolve Protocol
Cutting-edge medical science meets blockchain-driven technology to create new opportunities to drive innovation.